| MeSH term | MeSH ID | Detail |
|---|---|---|
| Cutaneous Fistula | D017577 | 1 associated lipids |
| Kleine-Levin Syndrome | D017593 | 1 associated lipids |
| Periodontal Attachment Loss | D017622 | 7 associated lipids |
| Soft Tissue Injuries | D017695 | 2 associated lipids |
| Community-Acquired Infections | D017714 | 8 associated lipids |
| Cytomegalovirus Retinitis | D017726 | 2 associated lipids |
| Tuberculosis, Multidrug-Resistant | D018088 | 6 associated lipids |
| Cardiovascular Abnormalities | D018376 | 2 associated lipids |
| Pneumonia, Bacterial | D018410 | 16 associated lipids |
| Soft Tissue Infections | D018461 | 2 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Haider RB et al. | A randomized-controlled study to compare the efficacy of sequential therapy with standard triple therapy for Helicobacter pylori eradication in an Irish population. | 2015 | Eur J Gastroenterol Hepatol | pmid:26287955 |
| Shallom SJ et al. | New Real-Time PCR Assays for Detection of Inducible and Acquired Clarithromycin Resistance in the Mycobacterium abscessus Group. | 2015 | J. Clin. Microbiol. | pmid:26269619 |
| Zagari RM et al. | Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. | 2015 | Dig Liver Dis | pmid:26253555 |
| Kasai A et al. | Prevalence and molecular analysis of macrolide-resistant Moraxella catarrhalis clinical isolates in Japan, following emergence of the highly macrolide-resistant strain NSH1 in 2011. | 2015 | J. Med. Microbiol. | pmid:25934551 |
| Flores-Gonzalez JC et al. | [Etiology, clinical presentation and outcome of severe viral acute childhood encephalitis (ECOVE study)]. | 2015 | Rev Neurol | pmid:26108903 |
| Ito A et al. | Increase in SCCmec type IV strains affects trends in antibiograms of meticillin-resistant Staphylococcus aureus at a tertiary-care hospital. | 2015 | J. Med. Microbiol. | pmid:25934550 |
| Bouilhat N et al. | High-level primary clarithromycin resistance of Helicobacter pylori in Morocco: a prospective multicenter molecular study. | 2015 | Helicobacter | pmid:25735573 |
| Guzman Vinasco L et al. | Acute suppurative parotitis caused by Streptococcus pneumoniae in an HIV-infected man. | 2015 | BMJ Case Rep | pmid:25733094 |
| Moriya S et al. | Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress‑mediated cell death in multiple myeloma cells. | 2015 | Int. J. Oncol. | pmid:25422130 |
| Tongtawee T et al. | High Prevalence of Helicobacter pylori Resistance to Clarithromycin: a Hospital-Based Cross-Sectional Study in Nakhon Ratchasima Province, Northeast of Thailand. | 2015 | Asian Pac. J. Cancer Prev. | pmid:26745073 |
| Alimadadi M et al. | Impact of creatinine clearance on Helicobacter pylori eradication rate in patients with peptic ulcer disease. | 2015 | Iran J Kidney Dis | pmid:26552348 |
| Karpiński TM et al. | Evaluation of antimicrobial resistance of Helicobacter pylori in the last 15 years in West Poland. | 2015 | Acta Microbiol Immunol Hung | pmid:26551571 |
| Hwang JJ et al. | Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication. | 2015 | World J. Gastroenterol. | pmid:26401089 |
| Salimi A et al. | Toxicity of macrolide antibiotics on isolated heart mitochondria: a justification for their cardiotoxic adverse effect. | 2016 | Xenobiotica | pmid:26068526 |
| Losurdo G et al. | Role of concomitant therapy for eradication: A technical note. | 2016 | World J. Gastroenterol. | pmid:27784977 |
| Zycinska K et al. | Antibiotic Treatment of Hospitalized Patients with Pneumonia Complicated by Clostridium Difficile Infection. | 2016 | Adv. Exp. Med. Biol. | pmid:27620311 |
| Bax HI et al. | Tigecycline Potentiates Clarithromycin Activity against Mycobacterium avium In Vitro. | 2016 | Antimicrob. Agents Chemother. | pmid:26883697 |
| Hirata Y et al. | Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen. | 2016 | Int. J. Infect. Dis. | pmid:27590563 |
| Liou JM et al. | Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. | 2016 | Lancet | pmid:27769562 |
| Campillo A et al. | [10-day triple therapy with esomeprazole 40 mg/12 h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection]. | 2016 | Gastroenterol Hepatol | pmid:27084668 |
| Zhou L et al. | Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial. | 2016 | Helicobacter | pmid:26104022 |
| Couture G et al. | [Second case of serum sickness-like reaction to claritrhomycin]. | 2016 | Presse Med | pmid:27542759 |
| Bugli F et al. | In vitro effect of clarithromycin and alginate lyase against helicobacter pylori biofilm. | 2016 | Biotechnol. Prog. | pmid:27535356 |
| Shichijo S et al. | Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice. | 2016 | J Dig Dis | pmid:27534444 |
| Morimoto K et al. | Macrolide-Resistant Mycobacterium avium Complex Lung Disease: Analysis of 102 Consecutive Cases. | 2016 | Ann Am Thorac Soc | pmid:27513168 |
| Lotfipour F et al. | Study of Antimicrobial Effects of Clarithromycin Loaded PLGA Nanoparticles against Clinical Strains of Helicobacter pylori. | 2016 | Drug Res (Stuttg) | pmid:25919643 |
| Miyaki A et al. | An assessment of the efficacy of first-line Helicobacter pylori-eradication therapy based on clarithromycin susceptibility. | 2016 | Minerva Gastroenterol Dietol | pmid:27304198 |
| Okano Y et al. | Miliary pulmonary nodules due to Mycobacterium xenopi in a steroid-induced immunocompromised patient successfully treated with chemotherapy: a case report. | 2016 | BMC Pulm Med | pmid:27287608 |
| Parize P et al. | Induction therapy with linezolid/clarithromycin combination for Mycobacterium chelonae skin infections in immunocompromised hosts. | 2016 | J Eur Acad Dermatol Venereol | pmid:25677464 |
| Akram FE et al. | A combination of silver nanoparticles and visible blue light enhances the antibacterial efficacy of ineffective antibiotics against methicillin-resistant Staphylococcus aureus (MRSA). | 2016 | Ann. Clin. Microbiol. Antimicrob. | pmid:27530257 |
| Fallone CA et al. | The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. | 2016 | Gastroenterology | pmid:27102658 |
| Bilgilier C et al. | Prevalence of clarithromycin-resistant Helicobacter pylori strains in gastric mucosa-associated lymphoid tissue lymphoma patients. | 2016 | Ann. Hematol. | pmid:27091350 |
| Root AA et al. | Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self-controlled study designs. | 2016 | Br J Clin Pharmacol | pmid:27090996 |
| Kazama I et al. | Clarithromycin Dose-Dependently Stabilizes Rat Peritoneal Mast Cells. | 2016 | Chemotherapy | pmid:27088971 |
| Huynh VA et al. | [Fixed drug eruption to clarithromycin: The importance of challenge tests in diagnosis]. | 2016 | Ann Dermatol Venereol | pmid:27080820 |
| EmiralioÄŸlu N et al. | Pulmonary Mycobacterium abscessus Infection in a Patient with Triple A Syndrome. | 2016 | J. Trop. Pediatr. | pmid:27080471 |
| Graham DY and Dore MP | Helicobacter pylori therapy: a paradigm shift. | 2016 | Expert Rev Anti Infect Ther | pmid:27077447 |
| Guirao-Arrabal E et al. | Clarithromycin plus linezolid as a sequential therapy for implantable-cardioverter-defibrillator infection caused by coagulase-negative staphylococci. | 2016 | Rev Esp Quimioter | pmid:26888341 |
| Friedman ND et al. | Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort. | 2016 | Antimicrob. Agents Chemother. | pmid:26883709 |
| Chua CS et al. | The efficacy of blueberry and grape seed extract combination on triple therapy for Helicobacter pylori eradication: a randomised controlled trial. | 2016 | Int J Food Sci Nutr | pmid:26883189 |
| Meng X et al. | [Antibiotic resistance of Helicobacter pylori clinical isolates in Hebei Province]. | 2016 | Zhonghua Yi Xue Za Zhi | pmid:26879786 |
| Bakshi SS | Outcome evaluation of clarithromycin, metronidazole and lansoprazole regimens in Helicobacter pylori positive or negative children with resistant otitis media with effusion. | 2016 | J Laryngol Otol | pmid:26878377 |
| Mukai S et al. | Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines. | 2016 | Int. J. Oncol. | pmid:26718641 |
| Hassan ST et al. | In vitro synergistic effect of Hibiscus sabdariffa aqueous extract in combination with standard antibiotics against Helicobacter pylori clinical isolates. | 2016 | Pharm Biol | pmid:26731378 |
| Çağan-Appak Y et al. | Clarithromycin resistance and 23S rRNA gene point mutations of Helicobacter pylori infection in children. | 2016 | Turk. J. Pediatr. | pmid:28276208 |
| Thung I et al. | Review article: the global emergence of Helicobacter pylori antibiotic resistance. | 2016 | Aliment. Pharmacol. Ther. | pmid:26694080 |
| Kamiya K et al. | Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan for Helicobacter pylori. | 2016 | J. Dermatol. | pmid:26508502 |
| Oh B et al. | The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial. | 2016 | Helicobacter | pmid:26395781 |
| Lee J et al. | A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM. | 2016 | J. Matern. Fetal. Neonatal. Med. | pmid:26373262 |
| Tsujimae M et al. | A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori. | 2016 | Digestion | pmid:28030862 |